Cargando…
Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
BACKGROUND: The prognosis of children with acute monocytic leukemia (AML‐M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML‐M5 children. METHODS: We inclu...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286455/ https://www.ncbi.nlm.nih.gov/pubmed/32216042 http://dx.doi.org/10.1002/cam4.3023 |
_version_ | 1783544879801958400 |
---|---|
author | Liu, Li‐Peng Zhang, Ao‐Li Ruan, Min Chang, Li‐Xian Liu, Fang Chen, Xia Qi, Ben‐Quan Zhang, Li Zou, Yao Chen, Yu‐Mei Chen, Xiao‐Juan Yang, Wen‐Yu Guo, Ye Zhu, Xiao‐Fan |
author_facet | Liu, Li‐Peng Zhang, Ao‐Li Ruan, Min Chang, Li‐Xian Liu, Fang Chen, Xia Qi, Ben‐Quan Zhang, Li Zou, Yao Chen, Yu‐Mei Chen, Xiao‐Juan Yang, Wen‐Yu Guo, Ye Zhu, Xiao‐Fan |
author_sort | Liu, Li‐Peng |
collection | PubMed |
description | BACKGROUND: The prognosis of children with acute monocytic leukemia (AML‐M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML‐M5 children. METHODS: We included 132 children with AML‐M5. Overall survival (OS) and progression‐free survival (PFS) were documented. Cox regression was performed to evaluate the potential risk factors of prognosis. RESULTS: The 5‐year‐OS was 46.0% (95% confidence intervals, 41.6%‐50.4%) in all patients. There was significantly lower OS in the age ≤ 3 years old (P = .009) and hyperleukocytosis (P < .001). The FMS‐like tyrosine kinase 3 (FLT3)‐internal tandem duplication (ITD) and MLL‐rearrangement carriers were associated with fewer survivors in all patients (37.1% and 36.7%) and chemotherapy‐only group (19.0% and 35.0%). Notably, the number of survivor with MLL‐rearrangement did not increase in hematopoietic stem cell transplant (HSCT) group. According to the Cox regression analysis, HSCT was a significantly favorable factor (P = .001), while hyperleukocytosis, age ≤ 3 years old, and BM blast ≥ 70% adversely affected the OS in all patients (all P < .05). Additionally, FLT3‐ITD was a risk factor for OS in the chemotherapy‐only group (P = .023), while hyperleukocytosis and age ≤ 3 years independently contributed to poor PFS (both P < .05). In comparison to the standard‐risk group, significant poorer outcome was found in the high‐risk group (both P < .005). CONCLUSIONS: We propose that AML‐M5 children with any of MLL‐rearrangement, FLT3‐ITD, hyperleukocytosis, BM blast ≥ 70%, or age ≤ 3 years old are classified into the high‐risk group, and HSCT is beneficial especially in patients with FLT3‐ITD mutation, hyperleukocytosis, and age ≤ 3 years old. Importantly, the choice of HSCT should be made more carefully in children with MLL‐rearrangement for its suboptimal performance. |
format | Online Article Text |
id | pubmed-7286455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72864552020-06-11 Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia Liu, Li‐Peng Zhang, Ao‐Li Ruan, Min Chang, Li‐Xian Liu, Fang Chen, Xia Qi, Ben‐Quan Zhang, Li Zou, Yao Chen, Yu‐Mei Chen, Xiao‐Juan Yang, Wen‐Yu Guo, Ye Zhu, Xiao‐Fan Cancer Med Clinical Cancer Research BACKGROUND: The prognosis of children with acute monocytic leukemia (AML‐M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML‐M5 children. METHODS: We included 132 children with AML‐M5. Overall survival (OS) and progression‐free survival (PFS) were documented. Cox regression was performed to evaluate the potential risk factors of prognosis. RESULTS: The 5‐year‐OS was 46.0% (95% confidence intervals, 41.6%‐50.4%) in all patients. There was significantly lower OS in the age ≤ 3 years old (P = .009) and hyperleukocytosis (P < .001). The FMS‐like tyrosine kinase 3 (FLT3)‐internal tandem duplication (ITD) and MLL‐rearrangement carriers were associated with fewer survivors in all patients (37.1% and 36.7%) and chemotherapy‐only group (19.0% and 35.0%). Notably, the number of survivor with MLL‐rearrangement did not increase in hematopoietic stem cell transplant (HSCT) group. According to the Cox regression analysis, HSCT was a significantly favorable factor (P = .001), while hyperleukocytosis, age ≤ 3 years old, and BM blast ≥ 70% adversely affected the OS in all patients (all P < .05). Additionally, FLT3‐ITD was a risk factor for OS in the chemotherapy‐only group (P = .023), while hyperleukocytosis and age ≤ 3 years independently contributed to poor PFS (both P < .05). In comparison to the standard‐risk group, significant poorer outcome was found in the high‐risk group (both P < .005). CONCLUSIONS: We propose that AML‐M5 children with any of MLL‐rearrangement, FLT3‐ITD, hyperleukocytosis, BM blast ≥ 70%, or age ≤ 3 years old are classified into the high‐risk group, and HSCT is beneficial especially in patients with FLT3‐ITD mutation, hyperleukocytosis, and age ≤ 3 years old. Importantly, the choice of HSCT should be made more carefully in children with MLL‐rearrangement for its suboptimal performance. John Wiley and Sons Inc. 2020-03-26 /pmc/articles/PMC7286455/ /pubmed/32216042 http://dx.doi.org/10.1002/cam4.3023 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Liu, Li‐Peng Zhang, Ao‐Li Ruan, Min Chang, Li‐Xian Liu, Fang Chen, Xia Qi, Ben‐Quan Zhang, Li Zou, Yao Chen, Yu‐Mei Chen, Xiao‐Juan Yang, Wen‐Yu Guo, Ye Zhu, Xiao‐Fan Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
title | Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
title_full | Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
title_fullStr | Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
title_full_unstemmed | Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
title_short | Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
title_sort | prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286455/ https://www.ncbi.nlm.nih.gov/pubmed/32216042 http://dx.doi.org/10.1002/cam4.3023 |
work_keys_str_mv | AT liulipeng prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT zhangaoli prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT ruanmin prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT changlixian prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT liufang prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT chenxia prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT qibenquan prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT zhangli prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT zouyao prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT chenyumei prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT chenxiaojuan prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT yangwenyu prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT guoye prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia AT zhuxiaofan prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia |